Haemonetics Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Haemonetics Corporation's yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 58.5 times by its yearly operating cash. Higher than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 6.0 times. Higher than 89% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$172Over the last 3 years, every $100 of reported profit came with $172 of operating cash.
Higher than 65% of Healthcare companies in United States.
Self-Funding Ratio
6.0×Over the last 3 years its own operating cash covered its investment spending (capex) 6.0 times.
Higher than 89% of Healthcare companies in United States.
Cash Locked Ratio
$35For every $100 of sales, $35 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $32 tied up three years earlier.
More money tied up than 75% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$11Sales grew 14% in 3 years, but profit fell: $11 less profit per $100 of extra sales.
Lower than 74% of Healthcare companies in United States.
Asset Productivity Ratio
+14% / +24%In 3 years sales changed by +14% while total assets changed by +24%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
58.5×Debt due within a year is covered 58.5 times by its yearly operating cash.
Higher than 96% of Healthcare companies in United States.
Cash Cushion Ratio
−19%Debt, after subtracting cash, equals 19% of its market value (net debt).
Lower than 83% of Healthcare companies in United States.
Tangible Assets Ratio
54%Of every $100 the company owns, $54 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 75% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 84% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Haemonetics Corporation owes $0.65 for every $1 it owns. Net profit fell 42% in the year to Mar 2026, and shrank 6% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Mar 2026.
P/E ratio
56.1Investors pay $56.1 for every $1 of Haemonetics Corporation's yearly profit, higher than 84% of Healthcare companies in United States.
P/B ratio
6.31The share price is 6.31 times Haemonetics Corporation's book value per share, higher than 77% of Healthcare companies in United States.
Market cap
$5.3 BThe total market value of all of Haemonetics Corporation's shares at today's price (share price × number of shares), larger than 85% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$837 MWhat Haemonetics Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$18.40Net worth divided by the number of shares. The share price of $116.16 is 6.3 times this, which is the P/B above.
Return on equity (ROE)
11.2%Haemonetics Corporation earned 11.2% on its shareholders' money over the last year, higher than 85% of Healthcare companies in United States.
Owes vs Owns
0.65×Haemonetics Corporation owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Dividend yield
NoneHaemonetics Corporation does not currently pay a dividend.
Revenue growth
-2%Revenue fell 2% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Profit growth
-42%Net profit fell 42% in the year to Mar 2026, and shrank 6% a year on average over 3 years.
Profit margin
7.3%Haemonetics Corporation keeps $7 of every $100 of revenue as net profit.
Cash quality
3.0×Cash from Haemonetics Corporation's business was 3.0× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
8.4×Haemonetics Corporation's operating profit covered its interest costs 8.4 times in the year to Mar 2026.
Cash vs debt
Net debtHaemonetics Corporation had $979 M more debt than cash (net debt) at Mar 2026.
Questions
What is Haemonetics Corporation's P/E ratio?
Investors pay $56.1 for every $1 of Haemonetics Corporation's yearly profit, higher than 84% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Haemonetics Corporation: $5.3 B ÷ $837 M (30 Jun 2026) = 6.3.
What is Haemonetics Corporation's return on equity?
Haemonetics Corporation earned 11.2% on its shareholders' money over the last year, higher than 85% of Healthcare companies in United States.
How much does Haemonetics Corporation owe compared with what it owns?
Haemonetics Corporation owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Does Haemonetics Corporation pay a dividend?
No. Haemonetics Corporation does not currently pay a dividend.
Is Haemonetics Corporation's revenue growing?
Revenue fell 2% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.